Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4DMedical Ltd ( (AU:4DX) ) has shared an update.
4DMedical Limited has received FDA clearance for its CT:VQ™ product, marking a significant advancement in respiratory diagnostics. CT:VQ™ is the first non-contrast, CT-based ventilation-perfusion imaging technology, offering a substantial improvement over traditional nuclear VQ scans by eliminating the need for radiotracers and integrating seamlessly with existing CT infrastructure. This innovation not only simplifies the imaging process but also expands access to advanced diagnostic capabilities across the U.S. healthcare system. The company anticipates capturing a significant portion of the $1.1 billion U.S. market and expects CT:VQ™ to drive long-term growth in demand for ventilation-perfusion scans, potentially displacing traditional nuclear VQ scans entirely.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global leader in respiratory imaging technology, specializing in advanced diagnostic solutions for lung health. The company focuses on developing innovative imaging products that enhance the diagnosis and management of respiratory conditions, with a significant market presence in the United States and Australia.
Average Trading Volume: 1,740,602
Technical Sentiment Signal: Buy
Current Market Cap: A$265.4M
See more data about 4DX stock on TipRanks’ Stock Analysis page.